Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.74 |
| ▸ | BCR | P11274 | 7/20 | 0.74 |
| ▸ | SRC | P12931 | 3/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | PRKCA | P17252 | 3/20 | 0.53 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKACG | P22612 | 1/20 | 0.46 |
| ▸ | PRKACB | P22694 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14041907 | 0.91 | ABL1 (0.72) | ABL1BCRSRCLCKPRKCA | |
| SCHEMBL7601457 | 0.90 | ABL1 (0.78) | ABL1BCRSRCLCKPRKCA | |
| Hydrochloric Acid SCHEMBL5205211 | 0.88 | ABL1 (0.76) | ABL1BCRSRCLCKPRKCA | |
| SCHEMBL2575958 | 0.87 | ABL1 (0.78) | ABL1BCRSRCLCKPRKCA | |
| SCHEMBL7466961 | 0.86 | SRC (0.63) | ABL1BCRSRCPRKCACAMKK2 | |
| SCHEMBL2392 | 0.85 | ABL1 (1.00) | ABL1BCRSRCPRKCAPDGFRA | |
| SCHEMBL29555505 | 0.85 | ABL1 (1.00) | ABL1BCRSRCPRKCAPDGFRA | |
| SCHEMBL13157373 | 0.85 | ABL1 (0.75) | ABL1BCRSRCLCKPRKCA | |
| SCHEMBL29366999 | 0.85 | ABL1 (1.00) | ABL1BCRSRCPRKCAPDGFRA | |
| SCHEMBL4735694 | 0.85 | ABL1 (0.71) | ABL1BCRSRCLCKPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | claimed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | claimed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | claimed |
| EP-1395261-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2004-03-10 | — | — | EP | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| WO-2002093164-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-11-21 | — | — | WO | claimed |
| EP-2385035-B1 | PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | HARBIN GLORIA PHARMACEUTICALS CO LTD (CN) | 2014-06-25 | — | — | EP | disclosed |
| US-8703771-B2 | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor | HARBIN GLORIA PHARMACEUTICALS CO., LTD. (CN) | 2014-04-22 | — | — | US | disclosed |
| US-8703771-B2 | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor | HARBIN GLORIA PHARMACEUTICALS CO., LTD. (CN) | 2014-04-22 | — | — | US | disclosed |
| US-8703771-B2 | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor | HARBIN GLORIA PHARMACEUTICALS CO., LTD. (CN) | 2014-04-22 | — | — | US | disclosed |
| US-20110319420-A1 | PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | HARBIN GLORIA PHARMACEUTICALS CO., LTD (CN) | 2011-12-29 | — | — | US | disclosed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | disclosed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-1395261-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | disclosed |
| WO-2002093164-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | ABL1 901/4885BCR 1338/4885SRC 796/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | ABL1 904/4885BCR 1230/4885SRC 724/4885 |
| US-20110319420-A1 | PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | KIT, ABL1, ABL2 | ABL1 2/4885BCR 7/4885SRC 50/4885 |
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | ABL1 2843/4885BCR 2315/4885SRC 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.